Cysview’s Safety Information Not Pretty In Pink, FDA Tells Photocure
This article was originally published in The Pink Sheet Daily
Executive Summary
Discussing a “pinkish tinge to the urine,” rather than blood, overplays the drug’s safety, the agency says in an advertising letter; also, the patient guide further confounds the safety presentation by first mentioning a common adverse reaction to the imaging drug as an uncommon post-marketing event, FDA says.
You may also be interested in...
Deals Of The Week: Karuna/Vanderbilt, Ipsen/Photocure, Lundbeck/Proximagen
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.